News stories about Edge Therapeutics (NASDAQ:EDGE) have been trending somewhat positive on Thursday, Accern reports. The research group identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Edge Therapeutics earned a news impact score of 0.13 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 44.3794030905662 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Biotech Stock Roundup: EDGE Falls, ALKS Down, FDA OK’s AMGN Drug Label Expansion (finance.yahoo.com)
- Edge Therapeutics Loses Edge on Failure of Late-Stage Study (zacks.com)
- With `moneyball’ for health care, Israel seeks edge in tech age (standard.net)
- Edge Therapeutics (EDGE) Stock Rating Lowered by Zacks Investment Research (americanbankingnews.com)
- Form 4 Edge Therapeutics, Inc. For: Mar 23 Filed by: Conti Kurt G (streetinsider.com)
Several research analysts recently issued reports on the company. BidaskClub cut Edge Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, March 30th. Credit Suisse Group cut Edge Therapeutics from an “outperform” rating to an “underperform” rating and set a $17.00 price objective on the stock. in a research note on Thursday, March 29th. JMP Securities cut Edge Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Wednesday, March 28th. Finally, Zacks Investment Research cut Edge Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 3rd.
Edge Therapeutics (NASDAQ:EDGE) last announced its earnings results on Thursday, March 1st. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.02).
In other news, insider R. Loch Macdonald sold 5,000 shares of the stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $13.75, for a total transaction of $68,750.00. Following the completion of the sale, the insider now owns 590,602 shares in the company, valued at approximately $8,120,777.50. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Brian A. Leuthner sold 2,500 shares of the stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $13.14, for a total value of $32,850.00. Following the sale, the chief executive officer now owns 82,736 shares of the company’s stock, valued at approximately $1,087,151.04. The disclosure for this sale can be found here. Insiders have sold a total of 17,500 shares of company stock worth $257,800 in the last ninety days. Insiders own 36.19% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This story was originally reported by BBNS and is the property of of BBNS. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://baseballnewssource.com/2018/04/05/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-edge-therapeutics-edge-share-price/2027908.html.
Edge Therapeutics Company Profile
Edge Therapeutics, Inc is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company’s initial product candidates target rare, acute, life-threatening neurological and other conditions.
Receive News & Ratings for Edge Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edge Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.